Bavarian Nordic (BAVA)
Nasdaq Copenhagen · Denmark · prices in DKK · close of 27 Oct 2026
Key indicators
| Last close | DKK 256.20 |
|---|---|
| 52-week range | 171.30 – 257.00 |
| Return, 1 month / 3 months | +17.6% / +46.5% |
| Return, 1 year / 3 years | +6.7% / +95.3% |
| Trend | Uptrend |
| RSI (14) | 80 |
| Volatility (1 year) | 34.8% |
| Worst drawdown (1 year) | -28.6% |
| Average daily value traded | 45.41M DKK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bavarian Nordic is a Danish vaccine company that develops and manufactures vaccines for infectious diseases. Its products include vaccines against smallpox and mpox, as well as travel vaccines and other immunisation products. The company serves public health authorities, governments and healthcare providers, with its operations based in Denmark and manufacturing and research activities in Europe and North America. It works on both marketed vaccines and development programmes for diseases with limited treatment options.
The shares are listed on the Nasdaq Copenhagen in Denmark under the code BAVA, and the price on this page is in Danish kroner (DKK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bavarian Nordic (BAVA) trades on the Nasdaq Copenhagen in Denmark. It last closed at DKK 256.20 on 27 October 2026.
Its price-based Market X-Ray is 72 out of 100 (a strong price profile), ranking 27 of 164 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 6.7% and over the last three months it rose 46.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Copenhagen
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 93 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 30.5% | ||
| From 52-week high | 0.0% | ||
| Momentum | 74 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 46.5% | ||
| 6-month return | 37.7% | ||
| 12-month return, skipping the last month | -9.3% | ||
| Stability (higher is calmer) | 43 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 34.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.6% | ||
| Liquidity | 84 · Strong | Trades actively. | |
| Average daily value traded | 45.41M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +5.9% |
|---|---|
| 1 month | +17.6% |
| 3 months | +46.5% |
| 6 months | +37.7% |
| 1 year | +6.7% |
| 3 years | +95.3% |
| 5 years | −15.3% |
Signals
| 50-day / 200-day average | 220.67 / 196.38 |
|---|---|
| Golden / death cross (60 days) | Golden, 36 days ago |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 5.27 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Copenhagen; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.